A new survey shows that three Big Pharmas have stolen the hearts of patient groups representing nearly 1 million people with cardiovascular conditions. | A new survey shows that three Big Pharmas have ...

However, MSN’s product is “consistent ... according to a list of negotiated prices published over the summer. Entresto is Novartis’ bestselling drug: For all of 2023, the heart failure ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming ... effective drug at the same list price as Gilenya.” ...

The third-quarter earnings season was at its peak this week for large drugmakers, with several companies — Eli Lilly LLY, ...

The earnings season for the drug and biotech sector kicked off last ... You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for the third quarter ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

The Watertown biotech is already working with pharma ... and Novartis AG to engineer capsids for gene therapy delivery. George Church-founded Dyno Therapeutics Inc. is adding to its list of ...

There is no statutory bar in the US for patenting drug-device combinations, including drug transdermal/thermal patches. In the US, patents for methods of treatment are also allowed. A list of a few ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.1 at the end of 2023 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its covid antibody cocktail as ...